Recent developments at Eli Lilly (NYSE:LLY) have highlighted significant strides in both product innovation and operational ...

Feb 20 - Eli Lilly (LLY, Financial ... Now, the firm is testing Kisunla, a monoclonal antibody whose drugs are hoped will clear amyloid plaques from the brain in the hope of preventing ...

SAN FRANCISCO, CA, USA and SUZHOU, China I March 14, 2025 I Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company ...

MariTide is a monthly injection that investors hope could compete against existing weight loss drugs from Novo Nordisk and ...

Treatment with donanemab (Kisunla) raised the risk of amyloid-related imaging abnormalities (ARIA) in people with early ...

("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and ...

(Reuters) -The U.S. Food and Drug Administration has revoked the emergency use authorization for four COVID-19 antibody-based ...

Eli Lilly's GLP-1 drugs Mounjaro and Zepbound are ... Kisunla is a monoclonal antibody that removes amyloid plaques from the brain, which are associated with the memory-robbing disease.

These are some of the areas where Eli Lilly, flush with cash from its GLP ... Kisunla is a monoclonal antibody that removes amyloid plaques from the brain, which are associated with the memory ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...

The peptides activate receptors of a gut hormone called GLP-1, while the antibody blocks receptors of another hormone called GIP. That's unlike Eli Lilly's obesity drug, Zepbound, which activates ...